Barclays PLC Acquires 143,072 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Barclays PLC raised its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 187.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 219,331 shares of the biotechnology company’s stock after purchasing an additional 143,072 shares during the quarter. Barclays PLC’s holdings in Aurinia Pharmaceuticals were worth $1,607,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. State Street Corp raised its position in shares of Aurinia Pharmaceuticals by 2.3% during the 3rd quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock valued at $21,587,000 after buying an additional 64,949 shares in the last quarter. PDT Partners LLC increased its stake in Aurinia Pharmaceuticals by 76.0% during the third quarter. PDT Partners LLC now owns 301,553 shares of the biotechnology company’s stock worth $2,210,000 after acquiring an additional 130,204 shares during the last quarter. Verition Fund Management LLC raised its position in Aurinia Pharmaceuticals by 209.0% during the third quarter. Verition Fund Management LLC now owns 58,518 shares of the biotechnology company’s stock valued at $429,000 after purchasing an additional 39,583 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Aurinia Pharmaceuticals by 172.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 32,078 shares of the biotechnology company’s stock valued at $235,000 after purchasing an additional 20,324 shares during the last quarter. Finally, FMR LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 44.8% in the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 3,919 shares during the period. 36.83% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $8.43, for a total value of $38,415.51. Following the completion of the sale, the director now owns 13,356 shares of the company’s stock, valued at approximately $112,591.08. This represents a 25.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. StockNews.com lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, December 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Aurinia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Stock Performance

Shares of Aurinia Pharmaceuticals stock opened at $9.20 on Friday. The company has a market capitalization of $1.32 billion, a PE ratio of -61.33 and a beta of 1.41. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $10.67. The stock’s fifty day moving average is $8.46 and its two-hundred day moving average is $7.00. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.